Curi Bio CSO Dr. Nicholas Geisse Wins 2020 'Big Idea of the Year' Award by XConomy

Curi Bio’s Chief Science Officer Dr. Nicholas Geisse has been awarded the Big Idea of the Year by Xconomy, an award that honors the people, companies, and organizations who are advancing transformative and revolutionary ideas in life sciences and healthcare. 

“We are honored to be selected as XConomy’s Big Idea of the Year Award and recognized for our next-generation technologies that make stem cells better at reproducing human drug responses in the petri dish,” said Curi CSO Dr. Nicholas Geisse. “Curi is making tremendous progress in developing innovative bioengineered human stem cell 2D and 3D platforms to accelerate the discovery of new medicines. Our success is driven by our diverse team of brilliant biologists and expert engineers – this is a team award and I would like to congratulate and thank all of my colleagues at Curi Bio.” 

Curi Bio’s preclinical discovery platform combines human iPSC-derived cell models, tissue-specific biosystems, and AI/ML-enabled phenotypic screening data—human cells, systems, and data—to accelerate the discovery of new medicines. Curi’s suite of human stem cell-based products and services enable scientists to build more mature and predictive human iPSC-derived tissues, with a focus on cardiac, musculoskeletal, and neuromuscular models, for discovery, safety, and efficacy testing of new drugs in development. Curi offers drug developers an integrated preclinical platform comprising innovative tissue-specific biosystems to create highly predictive human stem cell models and generate clinically-relevant data. Curi is closing the gap between preclinical data and human results, accelerating the discovery and development of safer, more effective medicines.

Since 2017, the mission of Xconomy’s annual award programs has been to provide the life sciences industry a moment to pause, recognize, and honor the very best we have to offer – the people, companies, and organizations that challenge the status quo and never accept what works as good enough.